Abstract:The WHO (World Health Organization) conducted an elimination of cervical cancer program using triple pillar intervention strategy to target 90%-70%-90% of women before the year 2030, including (1) a full vaccination of HPV (human papillomavirus) vaccine to 90% of girls <15 years of age; (2) a high-performance screening procedure to 70% of women during the reproductive age (at the age of 35 and 45 years of age); and (3) an appropriate and adequate treatment to 90% of women with confirmed diagnosis of cervical lesions. Among the aforementioned three pillars, a full HPV vaccination has been introduced in our previous review, of which we have discussed the policy and strategy of HPV vaccination in the world and also reviewed the efficacy of HPV vaccination, with a successful reduction of over 90% of HPV-associated neoplasms. The aims of the current review will target another pillar-an appropriate and adequate treatment to 90% of women with confirmed diagnosis of cervical lesions. Since the early-stage cervical cancer has a favorable outcome and the treatment recommendation has been established, therefore, the current review focuses on women with persistent, recurrent and metastatic cervical cancers (advanced cervical cancers), which are still a biggest challenge based on its extremely worse outcomes before the introduction of immune checkpoint inhibitors (ICIs). Integration of ICIs into conventional chemotherapy (paclitaxel-cisplatin) has become the new standard therapy for those patients with advanced cervical cancers. The recent clinical trials, such as KENOTE 826 and KENOTE A18 showing a dramatical improvement of both progression free survival and overall survival have approved the therapeutic efficacy of this combination as ICI plus paclitaxel-platinum (cisplatin or carboplatin) with/without bevacizumab to women with persistent, recurrent and metastatic cervical cancers.

Advances in immunotherapy for recurrent and metastatic cervical cancer

Advances in immunotherapy in cervical cancer

Advances in immunotherapy for cervical cancer: recent developments and future directions

New progress in immunotherapy of lung cancer

Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy

Immune checkpoint inhibitors in cervical cancer: Current status and research progress

Advances and Prospects in Cancer Immunotherapy

Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer

Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data

Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer

Current and emerging immunotherapies for recurrent cervical cancer.

Current strategies and prospects of cancer immunotherapy

Cervical Cancer Immunotherapy: Facts and Hopes

Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)

Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Advances in cervical cancer: current insights and future directions

Treatment strategies in cervical cancer: treatment of advanced disease

Advances in Targeted Therapy for the Treatment of Cervical Cancer

Update in Immunotherapy for Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck

Advances in immunotherapy for gastric cancer